| __timestamp | BioCryst Pharmaceuticals, Inc. | Mesoblast Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 54170000 |
| Thursday, January 1, 2015 | 13047000 | 65378000 |
| Friday, January 1, 2016 | 11253000 | 52263000 |
| Sunday, January 1, 2017 | 13933000 | 35072000 |
| Monday, January 1, 2018 | 29514000 | 27415000 |
| Tuesday, January 1, 2019 | 37121000 | 36983000 |
| Wednesday, January 1, 2020 | 67929000 | 50918000 |
| Friday, January 1, 2021 | 118818000 | 63586000 |
| Saturday, January 1, 2022 | 159371000 | 57967000 |
| Sunday, January 1, 2023 | 213894000 | 53107000 |
| Monday, January 1, 2024 | 23626000 |
Unleashing the power of data
In the ever-evolving biotech industry, understanding spending patterns can offer valuable insights into a company's strategic priorities. Over the past decade, Mesoblast Limited and BioCryst Pharmaceuticals, Inc. have demonstrated contrasting approaches in their Selling, General, and Administrative (SG&A) expenses.
From 2014 to 2023, BioCryst Pharmaceuticals saw a staggering increase in SG&A expenses, growing by nearly 2800%, peaking in 2023. This surge reflects their aggressive expansion and marketing strategies. In contrast, Mesoblast Limited's SG&A expenses remained relatively stable, with a slight decline of about 2% over the same period, indicating a more conservative approach.
Interestingly, 2024 data for BioCryst is missing, leaving room for speculation on their future trajectory. These spending patterns highlight the diverse strategies within the biotech sector, where financial decisions can significantly impact a company's market position and growth potential.
Pfizer Inc. or BioCryst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Sanofi and Mesoblast Limited
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and BioCryst Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Insmed Incorporated or BioCryst Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Bio-Techne Corporation and Mesoblast Limited
SG&A Efficiency Analysis: Comparing ADMA Biologics, Inc. and BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Bausch Health Companies Inc. and BioCryst Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Arrowhead Pharmaceuticals, Inc. and Mesoblast Limited
Operational Costs Compared: SG&A Analysis of Ligand Pharmaceuticals Incorporated and Mesoblast Limited
Mesoblast Limited vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Mesoblast Limited vs Evotec SE: SG&A Expense Trends